UA75656C2 - Crystalline co-precipitate of gatifloxacin and fatty acid utilized for pediatric formulations (variants) and method for its manufacture - Google Patents

Crystalline co-precipitate of gatifloxacin and fatty acid utilized for pediatric formulations (variants) and method for its manufacture Download PDF

Info

Publication number: UA75656C2
Authority: UA; Ukraine
Prior art keywords: crystalline; precipitate; gatifloxacin; fatty acid; specified
Prior art date: 2001-06-20

Application number

UA20031211971A

Other languages

English (en)

Ukrainian (uk)

Inventor

Krishnaswamy S Raghavan

Sunanda A Ranadive

Kenneth S Bembenek

Richard G Corrao

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-20

Filing date

2002-10-05

Publication date

2006-05-15

2002-10-05 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2006-05-15 Publication of UA75656C2 publication Critical patent/UA75656C2/uk

Links

XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 title claims abstract description 63
229960003923 gatifloxacin Drugs 0.000 title claims abstract description 63
239000002244 precipitate Substances 0.000 title claims abstract description 56
239000000203 mixture Substances 0.000 title claims abstract description 19
235000014113 dietary fatty acids Nutrition 0.000 title claims description 28
239000000194 fatty acid Substances 0.000 title claims description 28
229930195729 fatty acid Natural products 0.000 title claims description 28
150000004665 fatty acids Chemical class 0.000 title claims description 28
238000000034 method Methods 0.000 title claims description 28
238000009472 formulation Methods 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title description 2
235000019640 taste Nutrition 0.000 claims abstract description 32
235000021355 Stearic acid Nutrition 0.000 claims abstract description 23
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 17
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 16
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 16
235000021314 Palmitic acid Nutrition 0.000 claims abstract description 15
239000008117 stearic acid Substances 0.000 claims abstract description 14
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 8
239000007900 aqueous suspension Substances 0.000 claims abstract description 7
239000000725 suspension Substances 0.000 claims description 24
239000002904 solvent Substances 0.000 claims description 14
238000002360 preparation method Methods 0.000 claims description 13
238000003756 stirring Methods 0.000 claims description 11
238000010992 reflux Methods 0.000 claims description 8
150000002943 palmitic acids Chemical class 0.000 claims description 7
208000035473 Communicable disease Diseases 0.000 claims description 6
239000000945 filler Substances 0.000 claims description 6
238000001035 drying Methods 0.000 claims description 5
235000003599 food sweetener Nutrition 0.000 claims description 5
239000003765 sweetening agent Substances 0.000 claims description 5
RMJMZKDEVNTXHE-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1.FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1 RMJMZKDEVNTXHE-UHFFFAOYSA-N 0.000 claims description 3
238000010583 slow cooling Methods 0.000 claims description 3
238000011084 recovery Methods 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 8
241000124008 Mammalia Species 0.000 claims 6
238000009835 boiling Methods 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
235000019658 bitter taste Nutrition 0.000 abstract description 14
210000002784 stomach Anatomy 0.000 abstract description 4
238000010521 absorption reaction Methods 0.000 abstract description 3
229940072132 quinolone antibacterials Drugs 0.000 abstract description 2
239000000126 substance Substances 0.000 description 20
239000003814 drug Substances 0.000 description 15
230000001225 therapeutic effect Effects 0.000 description 13
229940079593 drug Drugs 0.000 description 11
238000001816 cooling Methods 0.000 description 9
238000002425 crystallisation Methods 0.000 description 9
230000008025 crystallization Effects 0.000 description 9
230000000873 masking effect Effects 0.000 description 8
239000008187 granular material Substances 0.000 description 7
210000000214 mouth Anatomy 0.000 description 7
239000002245 particle Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
230000008901 benefit Effects 0.000 description 6
238000010438 heat treatment Methods 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000000047 product Substances 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
230000000844 anti-bacterial effect Effects 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000013543 active substance Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000013078 crystal Substances 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
230000008569 process Effects 0.000 description 3
-1 quinolone compound Chemical class 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
239000004909 Moisturizer Substances 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000000975 co-precipitation Methods 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
229920001903 high density polyethylene Polymers 0.000 description 2
239000004700 high-density polyethylene Substances 0.000 description 2
238000002386 leaching Methods 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
230000001333 moisturizer Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
238000007711 solidification Methods 0.000 description 2
230000008023 solidification Effects 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
101100493820 Caenorhabditis elegans best-1 gene Proteins 0.000 description 1
206010013911 Dysgeusia Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010019670 Hepatic function abnormal Diseases 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
235000000556 Paullinia cupana Nutrition 0.000 description 1
240000003444 Paullinia cupana Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229940124350 antibacterial drug Drugs 0.000 description 1
229940126573 antibacterial therapeutic Drugs 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000008275 binding mechanism Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
235000013736 caramel Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229960001668 cefuroxime Drugs 0.000 description 1
JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000000975 dye Substances 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
229940100242 glycol stearate Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
238000009434 installation Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
238000005086 pumping Methods 0.000 description 1
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006068 taste-masking agent Substances 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
235000012141 vanillin Nutrition 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Seasonings (AREA)

UA20031211971A 2001-06-20 2002-10-05 Crystalline co-precipitate of gatifloxacin and fatty acid utilized for pediatric formulations (variants) and method for its manufacture UA75656C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29962501P	2001-06-20	2001-06-20
PCT/US2002/014596 WO2003000175A2 (en)	2001-06-20	2002-05-10	Pediatric formulation of gatifloxacin

Publications (1)

Publication Number	Publication Date
UA75656C2 true UA75656C2 (en)	2006-05-15

Family

ID=23155586

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20031211971A UA75656C2 (en)	2001-06-20	2002-10-05	Crystalline co-precipitate of gatifloxacin and fatty acid utilized for pediatric formulations (variants) and method for its manufacture

Country Status (29)

Country	Link
US (1)	US6589955B2 (pl)
EP (1)	EP1406572A4 (pl)
JP (1)	JP4617475B2 (pl)
KR (1)	KR100888519B1 (pl)
CN (1)	CN1264514C (pl)
AR (1)	AR034483A1 (pl)
AU (1)	AU2002345534B2 (pl)
BG (1)	BG108444A (pl)
BR (1)	BR0209692A (pl)
CA (1)	CA2450742A1 (pl)
CZ (1)	CZ20033487A3 (pl)
EE (1)	EE200400018A (pl)
GE (1)	GEP20053610B (pl)
HR (1)	HRP20031027A2 (pl)
HU (1)	HUP0401497A2 (pl)
IL (1)	IL158863A0 (pl)
IS (1)	IS7048A (pl)
MX (1)	MXPA03011451A (pl)
NO (1)	NO20035605D0 (pl)
NZ (1)	NZ529611A (pl)
PE (1)	PE20030126A1 (pl)
PL (1)	PL366559A1 (pl)
RU (1)	RU2288218C2 (pl)
SK (1)	SK14152003A3 (pl)
TW (1)	TWI224004B (pl)
UA (1)	UA75656C2 (pl)
WO (1)	WO2003000175A2 (pl)
YU (1)	YU100303A (pl)
ZA (1)	ZA200309173B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8383154B2 (en)	2004-05-11	2013-02-26	Egalet A/S	Swellable dosage form comprising gellan gum
US7838532B2 (en) *	2005-05-18	2010-11-23	Mpex Pharmaceuticals, Inc.	Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) *	2005-05-18	2013-10-01	Mpex Pharmaceuticals, Inc.	Aerosolized fluoroquinolones and uses thereof
US20070051418A1 (en) *	2005-09-02	2007-03-08	Rowles Brian A	Multilayer tubes
TW201010708A (en) *	2008-06-02	2010-03-16	Intervet Int Bv	Composition comprising an antibiotic and a corticosteroid
CN102325532B (zh) *	2008-10-07	2015-06-17	Mpex医药有限公司	用于减轻肺部炎症的左氧氟沙星吸入剂
AU2009302478B2 (en) *	2008-10-07	2015-09-03	Horizon Orphan Llc	Aerosol fluoroquinolone formulations for improved pharmacokinetics
LT2473170T (lt)	2009-09-04	2019-10-10	Horizon Orphan Llc	Aerozolizuoto levofloksacino panaudojimas cistinės fibrozės gydymui
CN102397546A (zh) *	2010-09-10	2012-04-04	广州自远生物科技有限公司	一种用于嗅觉或味觉敏感型动物的药物给药方法
CN102397552B (zh) *	2010-09-10	2016-06-08	广州自远生物科技有限公司	一种含喹诺酮类的药物复合制剂及其制备方法和应用
WO2014152332A1 (en)	2013-03-15	2014-09-25	Melinta Therapeutics, Inc.	Methods of treating infections in overweight and obese patients using antibiotics
WO2018129079A1 (en) *	2017-01-03	2018-07-12	Thermolife International, Llc	Method of isolating theacrine and composition comprising theacrine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RO88836A2 (ro)	1983-10-11	1986-03-31	Institutul Pentru Controlul De Stat Al Medicamentului Si Cercetari Farmaceutice,Ro	Procedeu de obtinere a comprimatelor cu eritromicina propionat de uz pediatric
JPH089597B2 (ja)	1986-01-21	1996-01-31	杏林製薬株式会社	選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
NL193682C (nl)	1987-05-14	2000-07-04	Glaxo Group Ltd	Beklede cefuroximaxetilsamenstelling.
US5405617A (en)	1991-11-07	1995-04-11	Mcneil-Ppc, Inc.	Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
IT1255792B (it)	1992-08-05	1995-11-16	Bayer Italia Spa	Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US5407921A (en)	1993-07-01	1995-04-18	Kao Corporation	Method for suppressing bitter taste
JP3449658B2 (ja)	1994-12-21	2003-09-22	杏林製薬株式会社	安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
DE19633480A1 (de)	1996-08-20	1998-02-26	Bayer Ag	Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
US5891469A (en)	1997-04-02	1999-04-06	Pharmos Corporation	Solid Coprecipitates for enhanced bioavailability of lipophilic substances
CA2227314A1 (en)	1997-01-24	1998-07-24	Hoechst Aktiengesellschaft	Preparation of concealed taste preparations of antibacterially active quinolone derivatives
GB9702799D0 (en)	1997-02-12	1997-04-02	Scherer Corp R P	Process for preparing solid pharmaceutical dosage forms
DE19820801A1 (de) *	1998-05-09	1999-11-25	Gruenenthal Gmbh	Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
DK1200129T3 (da)	1999-07-14	2009-01-12	Schering Plough Ltd	Smagsmaskering af orale, flydende quinolonfremstillinger ved anvendelse af ionbytterharpikser

2002
- 2002-05-09 US US10/143,487 patent/US6589955B2/en not_active Expired - Lifetime
- 2002-05-10 EE EEP200400018A patent/EE200400018A/xx unknown
- 2002-05-10 JP JP2003506621A patent/JP4617475B2/ja not_active Expired - Fee Related
- 2002-05-10 MX MXPA03011451A patent/MXPA03011451A/es active IP Right Grant
- 2002-05-10 CA CA002450742A patent/CA2450742A1/en not_active Abandoned
- 2002-05-10 PL PL02366559A patent/PL366559A1/pl not_active Application Discontinuation
- 2002-05-10 WO PCT/US2002/014596 patent/WO2003000175A2/en not_active Ceased
- 2002-05-10 AU AU2002345534A patent/AU2002345534B2/en not_active Ceased
- 2002-05-10 EP EP02744141A patent/EP1406572A4/en not_active Withdrawn
- 2002-05-10 CZ CZ20033487A patent/CZ20033487A3/cs unknown
- 2002-05-10 CN CNB02812409XA patent/CN1264514C/zh not_active Expired - Fee Related
- 2002-05-10 RU RU2003136068/04A patent/RU2288218C2/ru not_active IP Right Cessation
- 2002-05-10 YU YU100303A patent/YU100303A/sh unknown
- 2002-05-10 BR BR0209692-7A patent/BR0209692A/pt not_active IP Right Cessation
- 2002-05-10 HR HR20031027A patent/HRP20031027A2/hr not_active Application Discontinuation
- 2002-05-10 NZ NZ529611A patent/NZ529611A/en unknown
- 2002-05-10 GE GE5383A patent/GEP20053610B/en unknown
- 2002-05-10 SK SK1415-2003A patent/SK14152003A3/sk unknown
- 2002-05-10 HU HU0401497A patent/HUP0401497A2/hu unknown
- 2002-05-10 KR KR1020037016647A patent/KR100888519B1/ko not_active Expired - Fee Related
- 2002-05-10 IL IL15886302A patent/IL158863A0/xx unknown
- 2002-06-13 AR ARP020102227A patent/AR034483A1/es not_active Application Discontinuation
- 2002-06-14 TW TW091113074A patent/TWI224004B/zh not_active IP Right Cessation
- 2002-06-18 PE PE2002000518A patent/PE20030126A1/es not_active Application Discontinuation
- 2002-10-05 UA UA20031211971A patent/UA75656C2/uk unknown
2003
- 2003-11-20 IS IS7048A patent/IS7048A/is unknown
- 2003-11-25 ZA ZA200309173A patent/ZA200309173B/en unknown
- 2003-12-12 BG BG108444A patent/BG108444A/xx unknown
- 2003-12-16 NO NO20035605A patent/NO20035605D0/no unknown

Also Published As

Publication number	Publication date
EP1406572A4 (en)	2005-05-25
PL366559A1 (pl)	2005-02-07
CZ20033487A3 (cs)	2004-05-12
HRP20031027A2 (en)	2005-10-31
EP1406572A2 (en)	2004-04-14
IS7048A (is)	2003-11-20
KR20040011543A (ko)	2004-02-05
PE20030126A1 (es)	2003-02-08
HUP0401497A2 (hu)	2004-12-28
BG108444A (en)	2004-08-31
CN1264514C (zh)	2006-07-19
EE200400018A (et)	2004-04-15
MXPA03011451A (es)	2004-04-05
WO2003000175A3 (en)	2003-04-10
AR034483A1 (es)	2004-02-25
IL158863A0 (en)	2004-05-12
RU2003136068A (ru)	2005-02-10
GEP20053610B (en)	2005-09-12
JP2005500306A (ja)	2005-01-06
US6589955B2 (en)	2003-07-08
WO2003000175A2 (en)	2003-01-03
BR0209692A (pt)	2004-04-20
NO20035605D0 (no)	2003-12-16
SK14152003A3 (sk)	2004-06-08
TWI224004B (en)	2004-11-21
JP4617475B2 (ja)	2011-01-26
ZA200309173B (en)	2005-02-25
YU100303A (sh)	2006-08-17
KR100888519B1 (ko)	2009-03-11
US20030028025A1 (en)	2003-02-06
NZ529611A (en)	2006-02-24
CN1518449A (zh)	2004-08-04
CA2450742A1 (en)	2003-01-03
AU2002345534B2 (en)	2007-07-12
RU2288218C2 (ru)	2006-11-27

Publication	Publication Date	Title
RU2126257C1 (ru)	1999-02-20	Фармацевтическая композиция со сниженным горьким вкусом, содержащая азалид, и способ лечения бактериальной инфекции у млекопитающих (варианты)
DK168934B1 (da)	1994-07-11	Lægemiddeladsorbater, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende adsorbaterne
CA2377916C (en)	2008-03-11	Taste masked pharmaceutical liquid formulations
CA2703971C (en)	2017-10-10	Stabilized pediatric suspension of carisbamate
RU2241460C2 (ru)	2004-12-10	Фармацевтическая композиция цефуроксим аксетила с маскированным горьким вкусом
EP0293885A2 (en)	1988-12-07	Antibiotic-polymer compositions
JP3465820B2 (ja)	2003-11-10	トロバフロキサシン経口懸濁剤
RU2288218C2 (ru)	2006-11-27	Формы гатифлоксацина для применения в педиатрии
JPH04257587A (ja)	1992-09-11	置換カルボン酸のコデイン塩
AU2002345534A1 (en)	2003-06-19	Pediatric formulation of gatifloxacin
JP7403647B2 (ja)	2023-12-22	レバムロジピンベシル酸塩水和物含有組成物及びその調製方法
BR112014001530B1 (pt)	2022-05-31	Formas polimórficas do sal de sódio de 4-terc-butiln-[4-cloro-2-(1-óxi-piridina-4-carbonil)- fenil]-benzeno sulfonamida, composição farmacêutica e método de produção da mesma
US4772589A (en)	1988-09-20	Etoposide solution in NMP
JP6196730B2 (ja)	2017-09-13	セファロスポリンエステルを含む粒状固形製剤およびその製造方法
AU2010351281B2 (en)	2014-03-20	Ciprofloxacin dry syrup composition
MXPA00005554A (en)	2001-11-21	Trovafloxacin oral suspensions
CN111787906A (zh)	2020-10-16	含有无可可碱的可可的口服剂型
JPH04221379A (ja)	1992-08-11	チアプロフェン酸又はその不溶性若しくは部分可溶性エステルとシクロデキストリン又はそれらの誘導体との新規な複合体
WO1995023603A1 (de)	1995-09-08	Verwendung von in 6-stellung substituierten 2-amino-4,5,7,8-tetrahydro-6h-thiazolo 5,4-d azepinen als antidepressiva